Alfuzosin: a clinically uroselective α₁-blocker.

Area of Science:

• Pharmacology
• Urology

Background:

• Benign prostatic hyperplasia (BPH) causes lower urinary tract symptoms (LUTS).
• Convenient dosing for BPH management is crucial for patient adherence.
• Optimizing pharmacokinetic coverage is key for sustained symptom relief.

Purpose of the Study:

• To evaluate the efficacy and safety of a once-daily (o.d.) alfuzosin formulation for LUTS due to BPH.
• To assess the 24-hour effectiveness and tolerability of alfuzosin 10 mg o.d.
• To compare alfuzosin's effect on post-void residual urine and acute urinary retention against placebo.

Main Methods:

• Two double-blind, placebo-controlled phase III studies.
• Inclusion of 983 patients with LUTS suggestive of BPH.
• Evaluation of symptoms, flow rates, post-void residual urine, and adverse events.

Main Results:

• Alfuzosin 10 mg o.d. demonstrated 24-hour effectiveness in improving LUTS and flow rates.
• A significant decrease in post-void residual urine and acute urinary retention incidence was observed compared to placebo.
• The formulation was well-tolerated, with low incidence of postural hypotension and no significant blood pressure changes.
• Sexual side-effect profile was excellent, with no negative impact on quality of life.

Conclusions:

• Once-daily alfuzosin 10 mg is an effective and well-tolerated treatment for LUTS in BPH patients.
• This formulation offers improved dosing convenience and reduces risks associated with urinary retention.
• Alfuzosin 10 mg o.d. provides a favorable safety and tolerability profile, including sexual function.